Lund, Sweden, 12 January 2016 – NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has entered into a research partnership with University of Pennsylvania to enhance NeuroVive’s traumatic brain injury (TBI) research and development program. The research partnership will focus on an important unsolved problem in the medical field: nerve cell protection following moderate to severe brain trauma. The agreement between University of Pennsylvania and NeuroVive represents the expanding footprint beyond Europe into the US and will further advance the company’s understanding of and presence in the US market. The research collaboration is to provide more data on NeuroVive’s drug for the treatment of TBI, NeuroSTAT®, and will provide the company with additional preclinical data to support the regulatory filings for the TBI indication. NeuroVive will, via this partnership, get access to highly experienced scientists at University of Pennsylvania and the Children’s Hospital of Philadelphia whom have world-renown expertise in the area of TBI research. “The collaboration with Drs. Susan Margulies and Todd Kilbaugh at the University of Pennsylvania and the Children’s Hospital of Philadelphia is a very positive step for NeuroVive. The company is progressing its TBI research program through the CHIC trial and these next steps together with UPENN will provide us with supporting evidence which will complement the ongoing CHIC trial evaluating the safety of NeuroSTAT® in TBI. We hope to initiate the first studies during the first quarter of 2016” said Eskil Elmér, Chief Scientific Officer of NeuroVive. “Our team of researchers and scientists at the University of Pennsylvania and the Children’s Hospital of Philadelphia are enthusiastic about the opportunity to leverage our investigations at the forefront of TBI research to identify TBI treatments. This partnership with NeuroVive is designed as a pre-clinical translational bridge between potential therapies and clinical trials, to explore treatments for TBI where there are few options for patients” commented Dr. Susan S. Margulies, Professor in Bioengineering and Neurosurgery at the University of Pennsylvania. About TBI Traumatic brain injury (TBI) is brain damage that occurs after an external trauma to the head, where nerve cells receive immediate damage. The injury deteriorates for several days after the accident, often leading to a significant impact on the overall injurious effect. TBI afflicts approximately 1.7 million Americans annually with more than 52,000 associated deaths and 275,000 hospitalisations.* Both direct and indirect costs associated with TBI are estimated at more than $60 billion with a high number of patients left with moderate to severe disabilities requiring intensive care and support. It is hoped that better treatments for TBI, such as NeuroSTAT®, will lead to increased survival and greatly improved outcomes in terms of the ability of patients to function normally following moderate to severe TBI. About NeuroVive NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI), one candidate in preclinical development and two drug discovery platforms. NeuroSTAT® has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a Phase II study. CicloMulsion® is being evaluated in an on-going Phase II study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on NASDAQ Stockholm, Sweden. Disclaimer This release may contain forward-looking statements that can be identified by words such as “recommends,” “indicating,” “risk,” “recommended,” “believe,” “could,” “commitment,” “will,” “implications,” “supports,” “thought,” “designed,” “growing,” “continues,” or similar terms, or by expressed or implied discussions regarding potential marketing approvals for NeuroSTAT®, or regarding potential future revenues from NeuroSTAT®. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that NeuroSTAT® will be submitted or approved for sale in any market, or at any particular time. Nor can there be any guarantee that NeuroSTAT® will be commercially successful in the future. In particular, management’s expectations regarding NeuroSTAT® could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors. For investor relations and media questions, please contact: Johannes Nebel, Laika Consulting, Tel: +46 (0)735 81 71 68 or ir@neurovive.com It is also possible to arrange an interview with NeuroVive’s CEO Jan Nilsson at the above contacts. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com, www.neurovive.com NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 12 January 2016, at 08.30 CET. ---------------------------------------------------------------------- *U.S. Centers for Disease Control and Prevention (CDC). National Center for Injury Prevention and Control. Injury prevention and control: traumatic brain injury. For more information about TBI, please visit http://www.cdc.gov/TraumaticBrainInjury/data/index.html
NeuroVive enters strategic collaboration with University of
Top 10 Most Recent News Articles
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
FFR's Michigan Milestone and Major Robotics Update
Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...
Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival
Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
LONGi's Four Paths to Global Green Development
LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...
Continue Reading
Local Voices to Shape Mekong's Story in New Alliance
Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China
Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue ReadingTop 5 Most Recently Viewed Articles
Venezuela's Political Shift and Its Impact on Global Oil Markets
Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....
Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative
The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...
Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement
DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...
Continue Reading
Insights into the Growth of the Global Fondant Market Trends
Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...
Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details
Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...
Continue Reading